Performance Evaluation of G8, a High-Sensitivity Benchtop Preclinical PET/CT Tomograph
Conclusion: The overall performance demonstrates that the G8 can produce high-quality images for molecular imaging–based biomedical research. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Gu, Z., Taschereau, R., Vu, N. T., Prout, D. L., Silverman, R. W., Lee, J. T., Chatziioannou, A. F. Tags: Physics And Instrumentation Source Type: research

Erratum
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Tags: Erratum Source Type: research

Diastereomerically Pure 6R- and 6S-3'-Aza-2'-18F-Fluoro-5-Methyltetrahydrofolates Show Unprecedentedly High Uptake in Folate Receptor-Positive KB Tumors
Conclusion: We have successfully radiolabeled 6R- and 6S-3'-aza-2'-18F-fluoro-5-MTHF with 18F using the integrated approach. Our results suggest that both 6R- and 6S-3'-aza-2'-18F-fluoro-5-MTHF are promising reduced radiofolates for imaging FR-α–expressing cancers. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Boss, S. D., Muller, C., Siwowska, K., Schmid, R. M., Groehn, V., Schibli, R., Ametamey, S. M. Tags: Basic Source Type: research

Evaluation of a PET Radioligand to Image O-GlcNAcase in Brain and Periphery of Rhesus Monkey and Knock-Out Mouse
Conclusion: These results show that 18F-LSN3316612 is an excellent radioligand for imaging and quantifying OGA in rhesus monkeys and mice. On the basis of these data, 18F-LSN3316612 merits evaluation in humans. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Paul, S., Haskali, M. B., Liow, J.-S., Zoghbi, S. S., Barth, V. N., Kolodrubetz, M. C., Bond, M. R., Morse, C. L., Gladding, R. L., Frankland, M. P., Kant, N., Slieker, L., Shcherbinin, S., Nuthall, H. N., Zanotti-Fregonara, P., Hanover, J. A., Jesudason, Tags: Basic Source Type: research

11C-DPA-713 Versus 18F-GE-180: A Preclinical Comparison of Translocator Protein 18 kDa PET Tracers to Visualize Acute and Chronic Neuroinflammation in a Mouse Model of Ischemic Stroke
Conclusion: 11C-DPA-713 and 18F-GE-180 PET enable detection of neuroinflammation at acute and chronic time points after cerebral ischemia in mice. 11C-DPA-713 PET reflects the extent of microglial activation in infarcted distal middle cerebral artery occlusion mouse brain tissue more accurately than 18F-GE-180 and appears to be slightly more sensitive. These results highlight the potential of 11C-DPA-713 for tracking microglial activation in vivo after stroke and warrant further investigation in both preclinical and clinical settings. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Chaney, A., Cropper, H. C., Johnson, E. M., Lechtenberg, K. J., Peterson, T. C., Stevens, M. Y., Buckwalter, M. S., James, M. L. Tags: Basic Source Type: research

Behavioral Symptoms in Premanifest Huntington Disease Correlate with Reduced Frontal CB1R Levels
Conclusion: The association between behavioral symptoms and reduced prefrontal CB1R levels may provide new insight into the molecular basis of neuropsychiatric symptoms in pre-HD and suggest new therapeutic avenues. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Ceccarini, J., Ahmad, R., Van de Vliet, L., Casteels, C., Vandenbulcke, M., Vandenberghe, W., Van Laere, K. Tags: Clinical Source Type: research

Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles
Conclusion: 18F-MK-6240 exhibited favorable kinetics and high binding levels to brain regions with a plausible pattern for NFT deposition in AD subjects. In comparison, negligible tracer binding was observed in HE subjects. This pilot study suggests that simplified ratio methods such as SUVR can be used to quantify NFT binding. These results support further clinical development of 18F-MK-6240 for potential application in longitudinal studies. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Lohith, T. G., Bennacef, I., Vandenberghe, R., Vandenbulcke, M., Salinas, C. A., Declercq, R., Reynders, T., Telan-Choing, N. F., Riffel, K., Celen, S., Serdons, K., Bormans, G., Tsai, K., Walji, A., Hostetler, E. D., Evelhoch, J. L., Van Laere, K., Forma Tags: Clinical Source Type: research

Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab
Conclusion: Dose- and time-dependent reductions in the amyloid PET SUVR were consistently observed with aducanumab only in cortical regions prone to amyloid plaque deposition, regardless of the reference region used. These data support the hypothesis that florbetapir SUVR responses associated with aducanumab treatment are a result of specific dose- and time-dependent reductions in the amyloid burden in patients with Alzheimer disease. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Chiao, P., Bedell, B. J., Avants, B., Zijdenbos, A. P., Grand'Maison, M., ONeill, P., OGorman, J., Chen, T., Koeppe, R. Tags: Clinical Source Type: research

In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls
Conclusion: 18F-MK-6240 is a promising PET radioligand for in vivo imaging of neurofibrillary tau aggregates in AD with minimal off-target binding in the human brain. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Betthauser, T. J., Cody, K. A., Zammit, M. D., Murali, D., Converse, A. K., Barnhart, T. E., Stone, C. K., Rowley, H. A., Johnson, S. C., Christian, B. T. Tags: Clinical Source Type: research

Abnormal Ventilation-Perfusion Scan Is Associated with Pulmonary Hypertension in Sickle Cell Adults
Pulmonary hypertension (PH) in adults with sickle cell disease (SCD) is associated with early mortality. Chronic thromboembolic PH (CTEPH) is an important complication and contributor to PH in SCD but is likely underappreciated. Guidelines recommend ventilation–perfusion (V/Q) scintigraphy as the imaging modality of choice to exclude CTEPH. Data on V/Q scanning are limited in SCD. Our objective was to compare the performance of V/Q scanning with that of CT pulmonary angiography (CTPA) and to report clinical outcomes associated with abnormal V/Q findings. Methods: Laboratory data, echocardiography, 6-min-walk testing,...
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Mehari, A., Igbineweka, N., Allen, D., Nichols, J., Thein, S. L., Weir, N. A. Tags: Clinical Source Type: research

Ventricular Tachycardia (VT) Substrate Characteristics: Insights from Multimodality Structural and Functional Imaging of the VT Substrate Using Cardiac MRI Scar, 123I-Metaiodobenzylguanidine SPECT Innervation, and Bipolar Voltage
Postischemic adaptation results in characteristic myocardial structural and functional changes in the ventricular tachycardia (VT) substrate. The aim of this study was to compare myocardial structural and functional adaptations (late gadolinium enhancement/abnormal innervation) with detailed VT mapping data to identify regional heterogeneities in postischemic changes. Methods: Fifteen patients with ischemic cardiomyopathy and drug-refractory VT underwent late gadolinium enhancement cardiac MRI (CMR), 123I-metaiodobenzylguanidine SPECT, and high-resolution bipolar voltage mapping to assess fibrosis (>3 SDs), abnormal innervation (
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Imanli, H., Ume, K. L., Jeudy, J., Bob-Manuel, T., Smith, M. F., Chen, W., Abdulghani, M., Ghzally, Y., Mahat, J. B., Itah, R., Restrepo, A., See, V. Y., Shorofsky, S., Dilsizian, V., Dickfeld, T. Tags: Clinical Source Type: research

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
The prostate-specific membrane antigen (PSMA)–targeted radiotracers 68Ga/177Lu-PSMA-I&T and 99mTc-PSMA-I&S (for imaging and surgery) are currently successfully used for clinical PET imaging, radionuclide therapy, and radioguided surgery of metastatic prostate cancer. To additionally exploit the high sensitivity and spatial resolution of fluorescence imaging for improved surgical guidance, a PSMA-I&T–based hybrid tracer, PSMA-I&F (DOTAGA-k(Sulfo-Cy5)-y-nal-k-Sub-KuE), has been developed and evaluated. Methods: The in vitro PSMA-targeting efficiency of PSMA-I&F, the reference PSMA-I&T, and...
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Schottelius, M., Wurzer, A., Wissmiller, K., Beck, R., Koch, M., Gorpas, D., Notni, J., Buckle, T., van Oosterom, M. N., Steiger, K., Ntziachristos, V., Schwaiger, M., van Leeuwen, F. W. B., Wester, H.-J. Tags: Basic Source Type: research

Modeling and Predicting Tumor Response in Radioligand Therapy
Conclusion: To our knowledge, the proposed method is the first attempt to solely use PET/CT and modeling methods to predict the PSMA-positive tumor volume after RLT. Internal validation shows that this is feasible with an acceptable accuracy. Improvement of the method and external validation of the model is ongoing. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Kletting, P., Thieme, A., Eberhardt, N., Rinscheid, A., DAlessandria, C., Allmann, J., Wester, H.-J., Tauber, R., Beer, A. J., Glatting, G., Eiber, M. Tags: Translational Source Type: research

Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma
Conclusion: CXCR4-directed RLT (in combination with additional radioimmunotherapy) is feasible as a conditioning regimen before allogeneic stem cell transplantation in diffuse large B-cell lymphoma. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Lapa, C., Hanscheid, H., Kircher, M., Schirbel, A., Wunderlich, G., Werner, R. A., Samnick, S., Kotzerke, J., Einsele, H., Buck, A. K., Wester, H.-J., Grigoleit, G. U. Tags: Clinical Source Type: research

Characterization of Noise and Resolution for Quantitative 177Lu SPECT/CT with xSPECT Quant
Conclusion: If the reconstruction parameters are chosen with care, both examined reconstructions can provide absolute quantitative SPECT images with high image quality (subcentimeter resolution at an acceptable noise build-up) as well as high quantitative accuracy (given a well-calibrated Flash3D conversion from counts to activity concentration). With its standardized (and traceable) activity determination, xSPECT Quant dispenses with site-specific calibration protocols, enabling a reliable activity determination comparable across sites, which is especially useful for multicentric molecular radiotherapy studies. (Source: J...
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Tran-Gia, J., Lassmann, M. Tags: Clinical Source Type: research

Advancing Targeted Radionuclide Therapy Through the National Cancer Institutes Small Business Innovation Research Pathway
This article summarizes the NCI SBIR funding solicitations for the development of TRTs and the research proposals funded through them. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Zakeri, K., Narayanan, D., Evans, G., Prasanna, P., Buchsbaum, J. C., Vikram, B., Capala, J. Tags: Clinical Source Type: research

18F-Flortanidazole Hypoxia PET Holds Promise as a Prognostic and Predictive Imaging Biomarker in a Lung Cancer Xenograft Model Treated with Metformin and Radiotherapy
Metformin may improve tumor oxygenation and thus radiotherapy response, but imaging biomarkers for selection of suitable patients are still under investigation. First, we assessed the effect of acute metformin administration on non–small cell lung cancer xenograft tumor hypoxia using PET imaging with the hypoxia tracer 18F-flortanidazole. Second, we verified the effect of a single dose of metformin before radiotherapy on long-term treatment outcome. Third, we examined the potential of baseline 18F-flortanidazole as a prognostic or predictive biomarker for treatment response. Methods: A549 tumor–bearing mice und...
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: De Bruycker, S., Vangestel, C., Van den Wyngaert, T., Pauwels, P., wyffels, L., Staelens, S., Stroobants, S. Tags: Basic Source Type: research

Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies
Conclusion: 64Cu-NOTA-trastuzumab was effectively targeted to the HER2-expressing tumor in vitro and in vivo, and it exhibited a relatively low absorbed dose due to a short residence time. Therefore, 64Cu-NOTA-trastuzumab could be applied to select the right patients and right timing for HER2 therapy, to monitor the treatment response after HER2-targeted therapy, and to detect distal or metastatic spread. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Woo, S.-K., Jang, S. J., Seo, M.-J., Park, J. H., Kim, B. S., Kim, E. J., Lee, Y. J., Lee, T. S., An, G. I., Song, I. H., Seo, Y., Kim, K. I., Kang, J. H. Tags: Translational Source Type: research

Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Mortimer, J. E., Shively, J. E. Tags: Translational Source Type: research

SNMMI Leadership Update: At Home and Worldwide, Collaboration is Key for the Field of Nuclear Medicine and Molecular Imaging
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Minoshima, S. Tags: SNMMI Newsline Source Type: research

ABNM Statement on ACMUI Changes in Authorized User Training and Education
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Segall, G. M. Tags: SNMMI Newsline Source Type: research

Institute for Advanced Medical Isotopes Planned at TRIUMF, Canadas Particle Accelerator Center
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

Biodistribution, Radiation Dosimetry, and Clinical Application of a Melanin-Targeted PET Probe, 18F-P3BZA, in Patients
Conclusion: Our study suggests that 18F-P3BZA is safe and compatible for clinical use. The first-in-human clinical application to melanoma showed favorable delineated tumors in patients, demonstrating the potential of 18F-P3BZA for diagnostic PET imaging of melanoma. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Ma, X., Wang, S., Wang, S., Liu, D., Zhao, X., Chen, H., Kang, F., Yang, W., Wang, J., Cheng, Z. Tags: Translational Source Type: research

Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer
On successful completion of this activity one should be able to judge the prognosis of patients harboring metastasized differentiated thyroid cancer (DTC); identify suitable treatment regimens, taking into account the characteristics of the tumor and the patient’s general condition; and know the basics of radioiodine treatment, tyrosine kinase treatment, and redifferentiation treatment for metastasized DTC. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Kreissl, M. C., Janssen, M. J. R., Nagarajah, J. Tags: Continuing Education Source Type: research

2018 SNMMI Highlights Lecture: Oncology and Therapy, Part 2
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Scott, A. Tags: SNMMI Newsline Source Type: research

Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Bodei, L., Herrmann, K., Baum, R. P., Kidd, M., Malczewska, A., Modlin, I. M. Tags: Editorials Source Type: research

This Month in JNM
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Tags: This Month in JNM Source Type: research

Discussions with Leaders: A Conversation Between Richard Wahl and Johannes Czernin
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Wahl, R. L., Czernin, J. Tags: Leadership Perspectives Source Type: research

Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Razmaria, A., Calais, J., Czernin, J. Tags: Editor ' s Page Source Type: research

There Is No Evidence to Support the Linear No-Threshold Model of Radiation Carcinogenesis
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Siegel, J. A., Sacks, B., Greenspan, B. S. Tags: Letters Source Type: research

The Effect of Including Bone in Dixon-Based Attenuation Correction for 18F-Fluciclovine PET/MRI of Prostate Cancer
The objective of this study was to evaluate the effect of including bone in Dixon-based attenuation correction for 18F-fluciclovine PET/MRI of primary and recurrent prostate cancer. Methods: 18F-fluciclovine PET data from 2 PET/MRI studies—one for staging of high-risk prostate cancer (28 patients) and one for diagnosis of recurrent prostate cancer (81 patients)—were reconstructed with a 4-compartment (reference) and 5-compartment attenuation map. In the latter, continuous linear attenuation coefficients for bone were included by coregistration with an atlas. The SUVmax and mean 50% isocontour SUV (SUViso) of pr...
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Elschot, M., Selnaes, K. M., Johansen, H., Kruger-Stokke, B., Bertilsson, H., Bathen, T. F. Tags: Physics and Instrumentation Source Type: research

Evaluation of Two Potent and Selective PET Radioligands to Image COX-1 and COX-2 in Rhesus Monkeys
Conclusion: The findings suggest that 11C-PS13 has adequate signal in monkeys to justify its extension to human subjects. In contrast, 11C-MC1 is unlikely to show significant signal in healthy humans, though it may be able to do so in inflammatory conditions. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Kim, M.-J., Shrestha, S. S., Cortes, M., Singh, P., Morse, C., Liow, J.-S., Gladding, R. L., Brouwer, C., Henry, K., Gallagher, E., Tye, G. L., Zoghbi, S. S., Fujita, M., Pike, V. W., Innis, R. B. Tags: Basic Source Type: research

The Use of Ostrich Eggs for In Ovo Research: Making Preclinical Imaging Research Affordable and Available
Conclusion: In ovo imaging with ostrich eggs and routine clinical scanners may allow broader application of this field of preclinical research, obviating costly dedicated equipment and reducing the number of animals needed for classic animal research. Further experiments are warranted to refine this novel approach, especially to reduce motion artifacts and improve monitoring of viability. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Freesmeyer, M., Kuehnel, C., Opfermann, T., Niksch, T., Wiegand, S., Stolz, R., Huonker, R., Witte, O. W., Winkens, T. Tags: Basic Source Type: research

Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes
Conclusion: We have demonstrated for the first time that T cells can be modified with DAbR1, enabling their in vivo tracking via PET and SPECT. The favorable biodistribution and high image contrast observed warrant further studies of this new reporter gene. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Krebs, S., Ahad, A., Carter, L. M., Eyquem, J., Brand, C., Bell, M., Ponomarev, V., Reiner, T., Meares, C. F., Gottschalk, S., Sadelain, M., Larson, S. M., Weber, W. A. Tags: Basic Source Type: research

Reporter Genes for PET Imaging of CAR T Cells Offers Insight into Adoptive Cell Transfer
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Larimer, B. M. Tags: Basic Source Type: research

Antibody-Based In Vivo PET Imaging Detects Amyloid-{beta} Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition
Conclusion: Several treatments for AD are in phase 2 and 3 clinical trials, but the possibility of studying treatment effects in vivo on the important, nonfibrillar, forms of Aβ is limited. This study demonstrated the ability of the Aβ protofibril–selective radioligand 124I-RmAb158-scFv8D3 to follow disease progression and detect treatment effects with PET imaging in tg-ArcSwe mice. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Meier, S. R., Syvanen, S., Hultqvist, G., Fang, X. T., Roshanbin, S., Lannfelt, L., Neumann, U., Sehlin, D. Tags: Basic Source Type: research

Evaluation of 18F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain
Conclusion: 18F-RO-948 appears to be a promising radioligand for quantitative imaging of tau in the brain of AD patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Kuwabara, H., Comley, R. A., Borroni, E., Honer, M., Kitmiller, K., Roberts, J., Gapasin, L., Mathur, A., Klein, G., Wong, D. F. Tags: Translational Source Type: research

Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects
11C-RO-963, 11C-RO-643, and 18F-RO-948 (previously referred to as 11C-RO6924963, 11C-RO6931643, and 18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers. Methods: Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of 11C-RO-963, 11C-RO-643, or 18F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subject...
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Wong, D. F., Comley, R. A., Kuwabara, H., Rosenberg, P. B., Resnick, S. M., Ostrowitzki, S., Vozzi, C., Boess, F., Oh, E., Lyketsos, C. G., Honer, M., Gobbi, L., Klein, G., George, N., Gapasin, L., Kitzmiller, K., Roberts, J., Sevigny, J., Nandi, A., Bras Tags: Translational Source Type: research

Monosodium Glutamate Reduces 68Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
We evaluated the ability of monosodium glutamate (MSG) to reduce salivary and kidney uptake of a prostate-specific membrane antigen (PSMA) radioligand without affecting tumor uptake. Methods: LNCaP tumor–bearing mice were intraperitoneally injected with MSG (657, 329, or 164 mg/kg) or phosphate-buffered saline (PBS). Fifteen minutes later, the mice were intravenously administered 68Ga-PSMA-11. PET/CT imaging and biodistribution studies were performed 1 h after administration. Results: Tumor uptake (percentage injected dose per gram [%ID]) was not statistically different between groups, at 8.42 ± 1.40 %ID in th...
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Rousseau, E., Lau, J., Kuo, H.-T., Zhang, Z., Merkens, H., Hundal-Jabal, N., Colpo, N., Lin, K.-S., Benard, F. Tags: Basic Source Type: research

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging
Recently, the standardized reporting and data system for prostate-specific membrane antigen (PSMA)–targeted PET imaging studies, termed PSMA-RADS version 1.0, was introduced. We aimed to determine the interobserver agreement for applying PSMA-RADS to imaging interpretation of 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET examinations in a prospective setting mimicking the typical clinical workflow at a prostate cancer referral center. Methods: Four readers (2 experienced readers (ERs,>3 y of PSMA-targeted PET interpretation experience) and 2 inexperienced readers (IRs,
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Werner, R. A., Bundschuh, R. A., Bundschuh, L., Javadi, M. S., Leal, J. P., Higuchi, T., Pienta, K. J., Buck, A. K., Pomper, M. G., Gorin, M. A., Lapa, C., Rowe, S. P. Tags: Clinical Source Type: research

One-Stop-Shop Whole-Body 68Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer
Conclusion: In our analysis, preoperative 1-stop-shop 68Ga-PSMA-11 PET/MRI performs at least equally for T and N stage prediction compared with nomograms in high-risk prostate cancer patients. Despite an improved prediction of the full final stage and the yield of additional anatomic information, the use of 68Ga-PSMA-11 PET/MRI warrants further prospective evaluation. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Thalgott, M., Duwel, C., Rauscher, I., Heck, M. M., Haller, B., Gafita, A., Gschwend, J. E., Schwaiger, M., Maurer, T., Eiber, M. Tags: Clinical Source Type: research

Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
Conclusion: Combination treatment with TRT + ICIs targets both tumor cells and immune cells and has potential as a therapeutic agent in patients with metastatic melanoma. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Choi, J., Beaino, W., Fecek, R. J., Fabian, K. P. L., Laymon, C. M., Kurland, B. F., Storkus, W. J., Anderson, C. J. Tags: Basic Source Type: research

A First-in-Human Study of 68Ga-Nanocolloid PET/CT Sentinel Lymph Node Imaging in Prostate Cancer Demonstrates Aberrant Lymphatic Drainage Pathways
Conclusion: SLN identification using 68Ga-nanocolloid PET/CT can be successfully performed. Nontraditional pathways of disease spread were identified, including drainage to pelvic bone and to perivesicular, mesorectal, inguinal, and Virchow nodes. The prevalence of both aberrant and nonlymphatic pathways of spread should be further investigated with this technique. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Doughton, J. A., Hofman, M. S., Eu, P., Hicks, R. J., Williams, S. Tags: Translational Source Type: research

Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials
Conclusion: Interobserver agreement using DS in DLBCL patients in I-PET and EoT-PET yields high OA and NA. The lower PA suggests that EoT-PET/CT treatment evaluation in daily practice and I-PET–adapted trials may benefit from dual reads and central review, respectively. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Burggraaff, C. N., Cornelisse, A. C., Hoekstra, O. S., Lugtenburg, P. J., De Keizer, B., Arens, A. I. J., Celik, F., Huijbregts, J. E., De Vet, H. C. W., Zijlstra, J. M., on behalf of the HOVON Imaging Working Group Tags: Clinical Source Type: research

Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer
Assessing therapy response of breast cancer bone metastases is challenging. In retrospective studies, serial 18F-FDG PET was predictive of time to skeletal-related events (tSRE) and time to progression (TTP). 18F-NaF PET improves bone metastasis detection compared with bone scanning. We prospectively tested 18F-FDG PET and 18F-NaF PET to predict tSRE, TTP, and overall survival (OS) in patients with bone-dominant metastatic breast cancer (MBC). Methods: Patients with bone-dominant MBC were imaged with 18F-FDG PET and 18F-NaF PET before starting new therapy (scan1) and again at a range of times centered around approximately ...
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Peterson, L. M., OSullivan, J., Wu, Q., Novakova-Jiresova, A., Jenkins, I., Lee, J. H., Shields, A., Montgomery, S., Linden, H. M., Gralow, J., Gadi, V. K., Muzi, M., Kinahan, P., Mankoff, D., Specht, J. M. Tags: Clinical Source Type: research

Feasibility of 18F-FDG Dose Reductions in Breast Cancer PET/MRI
Conclusion: Ten percent of the standard dose of 18F-FDG (reduction of ≤90%) results in clinically acceptable PET image quality in time-of-flight PET/MRI. The calculated radiation exposure would be comparable to the effective dose of a single digital mammogram. A reduction of radiation burden to this level might justify partial-body examinations with PET/MRI for dedicated indications. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Sah, B.-R., Ghafoor, S., Burger, I. A., ter Voert, E. E. G. W., Sekine, T., Delso, G., Huellner, M., Dedes, K. J., Boss, A., Veit-Haibach, P. Tags: Clinical Source Type: research

18F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study
In this study, we investigated 18F-alfatide II for identifying breast cancer and compared the performances between 18F-alfatide II and 18F-FDG. Methods: Forty-four female patients with suspected primary breast cancer were recruited. PET/CT images using 18F-alfatide II and 18F-FDG were acquired within 7 d. Tracer uptake in breast lesions was evaluated by visual analysis, and semiquantitative analysis with SUVmax and SUVmean. Results: Forty-two breast cancer lesions and 11 benign breast lesions were confirmed by histopathology in 44 patients. Both 18F-alfatide II and 18F-FDG had higher uptake in breast cancer lesions than in...
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Wu, J., Wang, S., Zhang, X., Teng, Z., Wang, J., Yung, B. C., Niu, G., Zhu, H., Lu, G., Chen, X. Tags: Clinical Source Type: research

Treatment of Primary Liver Tumors and Liver Metastases, Part 2: Non-Nuclear Medicine Techniques
Image-guided procedures are used worldwide in the management of primary liver tumors and liver metastases. These locoregional therapies include local tumor ablation and transarterial therapies and can occasionally downstage an inoperable patient to an operable status. In hepatocellular carcinoma, data have suggested that for tumors smaller than 2 cm ablation may be preferable to surgery. Similar results are emerging for colorectal cancer liver metastases. Catheter-directed therapies such as bland embolization, transarterial chemoembolization, and drug-eluting beads represent potential techniques that can provide survival b...
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Cornelis, F. H., Solomon, S. B. Tags: Continuing Education Source Type: research

Nuclear Neuroimaging in Social Anxiety Disorder: A Review
In psychiatric research, nuclear imaging complements MRI. A recent neuroimaging review of social anxiety disorder focused predominantly on MRI, omitting the contribution of nuclear imaging methods. Nuclear imaging investigations of neural activity are sparse but have generally yielded results consistent with studies performed using MRI. Evidence for disturbances in neurotransmitter systems in social anxiety disorder is limited but suggestive of both serotonergic and dopaminergic dysfunction. Research focusing on additional molecular targets using existing and novel tracers, combined with recent technologic innovations and ...
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Doruyter, A. G., Dupont, P., Stein, D. J., Lochner, C., Warwick, J. M. Tags: The State of the Art Source Type: research

Are We Approaching the End of the Linear No-Threshold Era?
The linear no-threshold (LNT) model for radiation-induced cancer was adopted by national and international advisory bodies in the 1950s and has guided radiation protection policies worldwide since then. The resulting strict regulations have increased the compliance costs for the various uses of radiation, including nuclear medicine. The concerns about low levels of radiation due to the absence of a threshold have also resulted in adverse consequences. Justification of the LNT model was based on the concept that low levels of radiation increase mutations and that increased mutations imply increased cancers. This concept may...
Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Doss, M. Tags: Issues and Controversies Source Type: research